Search
Now showing items 1-7 of 7
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants.
(
Massachusetts Medical Society
, 2021 , Other)
The messenger RNA vaccine BNT162b2 (Pfizer–BioNTech) has 95% efficacy against coronavirus disease 2019 (Covid-19). Qatar launched a mass immunization campaign with this vaccine on December 21, 2020. As of March 31, 2021, ...
Protection against the omicron variant from previous SARS-CoV-2 infection
(
Massachusetts Medical Society
, 2022 , Other)
Natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits strong protection against reinfection with the B.1.1.7 (alpha),1,2 B.1.351 (beta),1 and B.1.617.2 (delta)3 variants. However, the ...
COVID-19 Disease Severity in Persons Infected with Omicron BA.1 and BA.2 Sublineages and Association with Vaccination Status
(
American Medical Association
, 2022 , Other)
[No abstract available]
Associations of Vaccination and of Prior Infection with Positive PCR Test Results for SARS-CoV-2 in Airline Passengers Arriving in Qatar
(
American Medical Association
, 2021 , Other)
The SARS-CoV-2 pandemic has severely affected international travel. With efficacious COVID-19 vaccines available, Qatar implemented a pilot program between February 18 and April 26, 2021, to ease travel restrictions by ...
Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2
(
Massachusetts Medical Society
, 2022 , Other)
More than 2 years into the coronavirus disease 2019 (Covid-19) pandemic, the global population carries heterogeneous immune histories derived from various exposures to infection, viral variants, and vaccination.1 Evidence ...
Protection against Reinfection with the Omicron BA.2.75 Subvariant
(
Massachusetts Medical Society
, 2023 , Other)
The BA.2.75 sublineage of the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may escape neutralizing antibodies. The BA.2.75 sublineage (primarily the BA.2.75.2 subvariant) ...
BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents
(
Elsevier
, 2023 , Other)
COVID-19 vaccine antigen dose might affect protection against SARS-CoV-2 infection,1, 2 but direct evidence to quantify this effect is absent. We conducted a matched, retrospective, cohort study using a regression ...